Viral vaccines and viral vectors used in biotherapeutic applications carry the risk of microbial contamination, which must be addressed.
Anissa Boumlic
Advertisement
Anissa Boumlic, PHD, is associate director EMEA vaccine and viral therapies, MilliporeSigma.
Articles by Anissa Boumlic
Advertisement
Latest Updated Articles
Ensuring Viral Safety of Viral Vaccines and VectorsSeptember 1st 2018
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
3
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
4
Janux’s JANX011 T-Cell Engager Shows Deep B-Cell Depletion in Phase 1 Healthy Volunteer Study
5